What is Elanco Animal Health Incorporated's earnings per share (EPS)?

Elanco Animal Health Incorporated (ELAN) reported diluted earnings per share of -$0.47 for fiscal year 2025. This represents a -169.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Elanco Animal Health Incorporated (ELAN) Financials

ELAN

Trailing 12 months to June 30, 2026

Revenue $5.0B +12.0% YoY

Net Income -$199.0M -145.9% YoY

EPS (Diluted) -$0.41 -147.7% YoY

Free Cash Flow $379.0M +5.0% YoY

Market Cap $11.2B as of Oct 6, 2026

Price / Sales 2.2x on $5.0B revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 1.7x on $6.6B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ELAN SEC filings page.

Elanco Animal Health Incorporated (ELAN) reported $5.0B in revenue over the twelve months to Jun 30, 2026, up 12.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ELAN FY2025 2026-10-04

Elanco's cash generation is stronger than reported earnings, while deleveraging and heavier reinvestment make results uneven.

Cash conversion diverged from accounting earnings in FY2025: the company reported a net loss of $232M but produced operating cash flow of $560M. With depreciation and amortization at $680M, the gap indicates that noncash charges materially shaped reported profit, so earnings alone understate operating cash produced.

Revenue recovered to $4.7B in FY2025 from $4.4B in FY2023, but the rebound did not translate into a structurally larger profit margin. Gross margin remained broadly flat around 55.0% across the period, indicating no broad margin expansion accompanied the recovery.

FY2025 operating cash flow of $560M converted to only $284M of free cash flow, so reinvestment consumed roughly half of internally generated operating cash. This occurred alongside debt-to-equity falling from 0.9x in FY2023 to 0.6x in FY2025, showing the company reduced leverage while continuing to fund capital spending.

Financial Health Signals

Financial Health Score 36/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Elanco Animal Health Incorporated's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Not available for Elanco Animal Health Incorporated, and counted as zero in the overall score.

Growth

Elanco Animal Health Incorporated's revenue grew 6.2% year-over-year to $4.7B, a solid pace of expansion. This earns a growth score of 42/100.

Leverage

Elanco Animal Health Incorporated has a moderate D/E ratio of 0.60. This balance of debt and equity financing earns a leverage score of 57/100.

Liquidity

Elanco Animal Health Incorporated's current ratio of 2.17 indicates adequate short-term liquidity, earning a score of 63/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Elanco Animal Health Incorporated has a free cash flow margin of 6.0%, earning a moderate score of 51/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Not available for Elanco Animal Health Incorporated, and counted as zero in the overall score.

Piotroski F-Score Neutral

5/9

Elanco Animal Health Incorporated passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

N/A

Elanco Animal Health Incorporated reported a net loss of $232.0M while generating $560.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.4B

YoY+10.2%

QoQ-0.2%

5Y CAGR+1.4%

Elanco Animal Health Incorporated generated $1.4B in revenue in Q2 2026. This represents an increase of 10.2% from the same quarter a year earlier. Against the prior quarter it is down 0.2%.

Net Income

$54.0M

YoY+390.9%

QoQ-5.3%

Elanco Animal Health Incorporated reported $54.0M in net income in Q2 2026. This represents an increase of 390.9% from the same quarter a year earlier. Against the prior quarter it is down 5.3%.

EPS (Diluted)

$0.11

YoY+450.0%

QoQ0.0%

Elanco Animal Health Incorporated earned $0.11 per diluted share (EPS) in Q2 2026. This represents an increase of 450.0% from the same quarter a year earlier. It is unchanged from the prior quarter.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

$244.0M

YoY+35.6%

QoQ+742.1%

5Y CAGR+13.1%

Elanco Animal Health Incorporated generated $244.0M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 35.6% from the same quarter a year earlier. Against the prior quarter it is up 742.1%.

Cash & Debt

$530.0M

YoY-1.7%

QoQ+23.8%

5Y CAGR-1.8%

Elanco Animal Health Incorporated held $530.0M in cash against $3.8B in long-term debt as of Q2 2026.

Shares Outstanding

500M

YoY+0.6%

QoQ0.0%

5Y CAGR+1.1%

Elanco Animal Health Incorporated had 500M shares outstanding in Q2 2026. This represents an increase of 0.6% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

58.3%

YoY+0.9pp

QoQ+1.1pp

Elanco Animal Health Incorporated's gross margin was 58.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.

Net Margin

4.0%

YoY+3.1pp

QoQ-0.2pp

5Y change+20.1pp

Elanco Animal Health Incorporated's net profit margin was 4.0% in Q2 2026, showing the share of revenue converted to profit. This is up 3.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.2 percentage points.

Return on Equity

0.8%

YoY+0.7pp

QoQ-0.1pp

5Y change+3.4pp

Elanco Animal Health Incorporated's ROE was 0.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.1 percentage points.

Operating Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$92.0M

YoY0.0%

QoQ-5.2%

Elanco Animal Health Incorporated invested $92.0M in research and development in Q2 2026. That is unchanged from the same quarter a year earlier. Against the prior quarter it is down 5.2%.

Capital Expenditures

$33.0M

YoY-42.1%

QoQ-35.3%

5Y CAGR+14.2%

Elanco Animal Health Incorporated invested $33.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 42.1% from the same quarter a year earlier. Against the prior quarter it is down 35.3%.

Share Buybacks

Not reported for Q2 2026.

ELAN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ELAN quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Revenue	$5.0B	$4.7B+6.2%	$4.4B+0.5%	$4.4B+0.1%	$4.4B-7.4%	$4.8B+45.6%	$3.3B+6.6%	$3.1B+0.1%	$3.1B+6.2%	$2.9B-0.8%	$2.9B
Cost of Revenue	$2.2B	$2.1B+5.9%	$2.0B+3.7%	$1.9B+0.9%	$1.9B-10.3%	$2.1B+27.9%	$1.7B+13.4%	$1.5B-6.6%	$1.6B+5.3%	$1.5B+6.0%	$1.4B
Gross Profit	$2.8B	$2.6B+6.4%	$2.4B-2.0%	$2.5B-0.5%	$2.5B-5.1%	$2.6B+63.9%	$1.6B+0.3%	$1.6B+7.2%	$1.5B+7.0%	$1.4B-7.3%	$1.5B
R&D Expenses	$371.0M	$368.0M+7.0%	$344.0M+5.2%	$327.0M+1.9%	$321.0M-13.0%	$369.0M+12.2%	$329.0M+21.9%	$270.0M+9.5%	$246.6M-2.0%	$251.7M-5.3%	$265.8M
SG&A Expenses	$1.5B	$1.4B+8.8%	$1.3B+2.3%	$1.3B+1.6%	$1.3B-9.8%	$1.4B+40.7%	$997.0M+31.2%	$760.0M+3.4%	$735.2M-5.7%	$779.8M-0.6%	$784.8M
Interest Expense	$248.0M	$220.0M-6.4%	$235.0M-15.2%	$277.0M+14.9%	$241.0M+2.1%	$236.0M+57.3%	$150.0M+89.9%	$79.0M+166.9%	$29.6M	$0	$0
Income Tax	$33.0M	$8.0M-94.7%	$150.0M+316.7%	$36.0M+500.0%	$6.0M+106.8%	-$88.0M+14.6%	-$103.0M-1130.0%	$10.0M-63.8%	$27.6M-64.7%	$78.1M+206.3%	$25.5M
Net Income	-$199.0M	-$232.0M-168.6%	$338.0M+127.5%	-$1.2B-1478.2%	-$78.0M+83.9%	-$483.0M+15.9%	-$574.0M-944.1%	$68.0M-21.4%	$86.5M+127.8%	-$310.7M-548.6%	-$47.9M
EPS (Basic)	N/A	-$0.47-169.1%	$0.68+127.2%	-$2.50-1462.5%	-$0.16+83.8%	-$0.99+23.8%	-$1.30-822.2%	$0.18-35.7%	$0.28+126.4%	-$1.06	N/A
EPS (Diluted)	-$0.41	-$0.47-169.1%	$0.68+127.2%	-$2.50-1462.5%	-$0.16+83.8%	-$0.99+23.8%	-$1.30-822.2%	$0.18-35.7%	$0.28+126.4%	-$1.06	N/A
Diluted Shares (Avg)	N/A	496M-0.2%	497M+1.0%	492M+0.8%	488M+0.2%	487M+10.4%	441M+19.2%	370M+18.0%	314M+7.0%	293M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$1.4B+10.2%	$1.4B+14.9%	$1.1B+12.2%	$1.1B+10.4%	$1.2B+4.8%	$1.2B-1.0%	$1.0B-1.4%	$1.0B-3.6%
Cost of Revenue	$570.0M+8.0%	$586.0M+15.1%	$555.0M+10.8%	$530.0M+7.7%	$528.0M+6.7%	$509.0M-1.2%	$501.0M-2.9%	$492.0M+1.0%
Gross Profit	$798.0M+11.9%	$785.0M+14.8%	$589.0M+13.5%	$607.0M+12.8%	$713.0M+3.5%	$684.0M-0.9%	$519.0M0.0%	$538.0M-7.4%
R&D Expenses	$92.0M0.0%	$97.0M+3.2%	$93.0M+14.8%	$89.0M+2.3%	$92.0M+3.4%	$94.0M+8.0%	$81.0M+2.5%	$87.0M+1.2%
SG&A Expenses	$449.0M+12.3%	$381.0M+11.7%	$338.0M+12.7%	$351.0M+8.7%	$400.0M+13.0%	$341.0M+1.2%	$300.0M+2.7%	$323.0M+3.2%
Interest Expense	$59.0M+22.9%	$57.0M+42.5%	$80.0M+73.9%	$52.0M-10.3%	$48.0M-26.2%	$40.0M-39.4%	$46.0M-31.3%	$58.0M-19.4%
Income Tax	$2.0M-85.7%	$30.0M+528.6%	$17.0M+139.5%	-$16.0M-108.2%	$14.0M-22.2%	-$7.0M+65.0%	-$43.0M-407.1%	$195.0M+19600.0%
Net Income	$54.0M+390.9%	$57.0M-14.9%	-$276.0M-3350.0%	-$34.0M-109.3%	$11.0M+122.0%	$67.0M+109.4%	-$8.0M+94.3%	$364.0M+133.2%
EPS (Basic)	$0.11+450.0%	$0.11-21.4%	-$0.56-2700.0%	-$0.07-109.5%	$0.02+120.0%	$0.14+133.3%	-$0.02+93.1%	$0.74+133.3%
EPS (Diluted)	$0.11+450.0%	$0.11-15.4%	-$0.56-2700.0%	-$0.07-109.6%	$0.02+120.0%	$0.13+116.7%	-$0.02+93.1%	$0.73+132.9%
Diluted Shares (Avg)	506M+1.2%	506M+1.4%	N/A	497M-0.2%	500M+1.2%	499M+0.6%	N/A	498M+1.0%

Not reported in any period shown, so not listed: Operating Income, EBITDA.

ELAN Balance Sheet

ELAN quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Total Assets	$13.4B+5.9%	$12.6B-12.2%	$14.4B-7.3%	$15.5B-6.0%	$16.5B-6.9%	$17.7B+96.9%	$9.0B+0.3%	$9.0B+0.2%	$8.9B	N/A
Current Assets	$3.5B+7.6%	$3.2B-5.6%	$3.4B+3.9%	$3.3B+0.2%	$3.3B-4.2%	$3.4B+44.0%	$2.4B-5.3%	$2.5B+17.9%	$2.1B	N/A
Cash & Equivalents	$545.0M+16.5%	$468.0M+33.0%	$352.0M+2.0%	$345.0M-45.9%	$638.0M+28.9%	$495.0M+48.2%	$334.0M-29.7%	$474.8M+46.8%	$323.4M+25.0%	$258.8M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.7B+10.4%	$1.6B-9.3%	$1.7B+12.8%	$1.5B+12.2%	$1.4B-13.1%	$1.6B+50.2%	$1.1B+4.6%	$1.0B-5.5%	$1.1B	N/A
Accounts Receivable	$873.0M+8.4%	$805.0M-4.4%	$842.0M+5.6%	$797.0M-4.3%	$833.0M-4.5%	$872.0M+6.7%	$816.9M+25.3%	$651.8M+14.9%	$567.4M	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$4.8B+8.3%	$4.4B-13.3%	$5.1B-15.0%	$6.0B-2.9%	$6.2B-0.9%	$6.2B+108.2%	$3.0B+1.1%	$3.0B-0.4%	$3.0B	N/A
Total Liabilities	$6.8B+4.5%	$6.5B-19.9%	$8.1B-0.8%	$8.2B-8.6%	$9.0B-2.7%	$9.2B+168.0%	$3.4B-8.5%	$3.8B+224.1%	$1.2B	N/A
Current Liabilities	$1.6B+21.4%	$1.3B+6.0%	$1.2B-27.1%	$1.7B+3.3%	$1.6B-20.7%	$2.1B+153.8%	$818.5M-15.7%	$970.7M+50.9%	$643.1M	N/A
Non-Current Liabilities	$5.2B+0.2%	$5.2B-24.6%	$6.9B+6.1%	$6.5B-11.2%	$7.3B+2.6%	$7.1B+172.5%	$2.6B-6.0%	$2.8B+439.5%	$516.9M	N/A
Long-Term Debt	$3.9B-7.8%	$4.3B-25.4%	$5.7B+5.3%	$5.4B-9.6%	$6.0B+8.1%	$5.6B+139.1%	$2.3B-4.6%	$2.4B	$0	N/A
Total Equity	$6.5B+7.4%	$6.1B-2.0%	$6.2B-14.6%	$7.3B-2.9%	$7.5B-11.2%	$8.5B+52.6%	$5.5B+6.7%	$5.2B-33.2%	$7.8B+10.9%	$7.0B
Retained Earnings	-$2.2B-11.9%	-$1.9B+14.8%	-$2.3B-116.5%	-$1.1B-8.0%	-$979.0M-105.2%	-$477.0M-665.8%	$84.3M+414.0%	$16.4M	$0	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$13.6B-1.3%	$13.2B+2.2%	$13.4B+5.9%	$13.6B+2.0%	$13.7B-0.2%	$12.9B-7.7%	$12.6B-12.2%	$13.3B-7.4%
Current Assets	$3.8B+5.1%	$3.6B+4.2%	$3.5B+7.6%	$3.5B+3.8%	$3.6B-9.9%	$3.4B-15.1%	$3.2B-5.6%	$3.4B-5.6%
Cash & Equivalents	$530.0M-1.7%	$428.0M-12.1%	$545.0M+16.5%	$505.0M+3.1%	$539.0M+29.6%	$487.0M+41.2%	$468.0M+33.0%	$490.0M+32.8%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.8B+5.9%	$1.7B+7.9%	$1.7B+10.4%	$1.7B+4.7%	$1.7B+3.7%	$1.6B-2.8%	$1.6B-9.3%	$1.6B-3.4%
Accounts Receivable	$1.1B+8.9%	$1.1B+11.8%	$873.0M+8.4%	$894.0M+6.4%	$989.0M-1.0%	$970.0M-1.8%	$805.0M-4.4%	$840.0M-7.8%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$4.8B+1.8%	$4.7B+4.8%	$4.8B+8.3%	$4.8B+3.0%	$4.8B+6.2%	$4.5B+0.7%	$4.4B-13.3%	$4.6B-5.7%
Total Liabilities	$7.0B+0.1%	$6.7B+2.0%	$6.8B+4.5%	$6.8B+0.6%	$7.0B-10.9%	$6.6B-17.3%	$6.5B-19.9%	$6.8B-17.7%
Current Liabilities	$1.9B+33.0%	$1.7B+31.0%	$1.6B+21.4%	$1.5B+10.1%	$1.4B+1.6%	$1.3B+3.0%	$1.3B+6.0%	$1.3B+4.4%
Non-Current Liabilities	$5.1B-8.1%	$5.1B-4.9%	$5.2B+0.2%	$5.3B-1.7%	$5.6B-13.6%	$5.3B-21.0%	$5.2B-24.6%	$5.4B-21.7%
Long-Term Debt	$3.8B-7.3%	$3.9B-10.0%	$3.9B-7.8%	$4.0B-8.1%	$4.1B-24.1%	$4.4B-24.0%	$4.3B-25.4%	$4.3B-26.5%
Total Equity	$6.6B-2.8%	$6.5B+2.3%	$6.5B+7.4%	$6.7B+3.5%	$6.8B+14.0%	$6.4B+4.9%	$6.1B-2.0%	$6.5B+6.3%
Retained Earnings	-$2.1B-10.6%	-$2.1B-12.9%	-$2.2B-11.9%	-$1.9B+1.9%	-$1.9B+18.8%	-$1.9B+16.5%	-$1.9B+14.8%	-$1.9B+9.5%

ELAN Cash Flow Statement

ELAN quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Operating Cash Flow	$617.0M	$560.0M+3.5%	$541.0M+99.6%	$271.0M-40.0%	$452.0M-6.4%	$483.0M+1278.0%	-$41.0M-118.3%	$224.0M-54.0%	$487.3M+180.4%	$173.8M+11.5%	$155.9M
Depreciation & Amortization	N/A	$680.0M+2.7%	$662.0M-4.6%	$694.0M+1.8%	$682.0M-4.7%	$716.0M+38.5%	$517.0M+64.6%	$314.0M+6.1%	$296.0M-7.0%	$318.4M+25.2%	$254.4M
Stock-Based Compensation	N/A	$68.0M+23.6%	$55.0M+19.6%	$46.0M-22.0%	$59.0M-10.6%	$66.0M+40.4%	$47.0M-4.1%	$49.0M+88.5%	$26.0M+4.0%	$25.0M+22.5%	$20.4M
Capital Expenditures	$238.0M	$276.0M+87.8%	$147.0M+5.0%	$140.0M-18.1%	$171.0M+7.5%	$159.0M+17.8%	$135.0M-3.6%	$140.0M+4.1%	$134.5M+36.4%	$98.6M-10.6%	$110.3M
Free Cash Flow	$379.0M	$284.0M-27.9%	$394.0M+200.8%	$131.0M-53.4%	$281.0M-13.3%	$324.0M+284.1%	-$176.0M-309.5%	$84.0M-76.2%	$352.8M+369.1%	$75.2M+64.9%	$45.6M
Investing Cash Flow	-$335.0M	-$279.0M-124.1%	$1.2B+785.2%	-$169.0M+5.6%	-$179.0M+66.2%	-$530.0M+88.9%	-$4.8B-1933.6%	-$235.0M-85.0%	-$127.0M+86.8%	-$964.6M-429.7%	-$182.1M
Financing Cash Flow	-$310.0M	-$275.0M+81.6%	-$1.5B-1697.6%	-$83.0M+84.9%	-$549.0M-361.4%	$210.0M-95.8%	$5.0B+1724.3%	-$305.0M-766.5%	-$35.2M-104.2%	$847.5M+666.5%	-$149.6M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$277.0M+16.9%	$13.0M+425.0%	$108.0M-39.0%	$219.0M+35.2%	$237.0M+18.5%	-$4.0M-300.0%	$177.0M+12.7%	$162.0M-18.2%
Depreciation & Amortization	$165.0M+2.5%	$172.0M+6.8%	$174.0M+6.1%	$168.0M+5.0%	$161.0M+5.2%	$161.0M-3.0%	$164.0M-4.1%	$160.0M-7.5%
Stock-Based Compensation	N/A	$21.0M+40.0%	N/A	N/A	N/A	$15.0M+36.4%	N/A	N/A
Capital Expenditures	$33.0M-42.1%	$51.0M-21.5%	$62.0M+31.9%	$92.0M+119.0%	$57.0M+67.6%	$65.0M+170.8%	$47.0M+14.6%	$42.0M+27.3%
Free Cash Flow	$244.0M+35.6%	-$38.0M+44.9%	$46.0M-64.6%	$127.0M+5.8%	$180.0M+8.4%	-$69.0M-213.6%	$130.0M+12.1%	$120.0M-27.3%
Investing Cash Flow	-$110.0M-96.4%	-$60.0M-3.4%	-$64.0M+28.9%	-$101.0M-108.1%	-$56.0M-69.7%	-$58.0M-256.8%	-$90.0M-157.1%	$1.2B+3555.6%
Financing Cash Flow	-$74.0M+52.6%	-$65.0M-225.0%	-$18.0M+43.8%	-$153.0M+88.6%	-$156.0M-67.7%	$52.0M+292.6%	-$32.0M+77.0%	-$1.3B-753.5%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ELAN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ELAN quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Gross Margin	55.0%+0.1pp	54.9%-1.4pp	56.3%-0.4pp	56.6%+1.4pp	55.3%+6.2pp	49.1%-3.1pp	52.1%+3.4pp	48.7%+0.4pp	48.3%-3.3pp	51.6%
Net Margin	-4.9%-12.5pp	7.6%+35.5pp	-27.9%-26.1pp	-1.8%+8.4pp	-10.1%+7.4pp	-17.5%-19.8pp	2.2%-0.6pp	2.8%+13.6pp	-10.8%-9.1pp	-1.6%
Return on Equity	-3.5%-9.1pp	5.5%+25.3pp	-19.8%-18.7pp	-1.1%+5.4pp	-6.4%+0.4pp	-6.8%-8.0pp	1.2%-0.4pp	1.7%+5.6pp	-4.0%-3.3pp	-0.7%
Return on Assets	-1.7%-4.4pp	2.7%+11.3pp	-8.6%-8.1pp	-0.5%+2.4pp	-2.9%+0.3pp	-3.2%-4.0pp	0.8%-0.2pp	1.0%+4.5pp	-3.5%	N/A
Current Ratio	2.17-0.3x	2.44-0.3x	2.75+0.8x	1.93-0.1x	1.99+0.3x	1.65-1.3x	2.90+0.3x	2.58-0.7x	3.30	N/A
Debt-to-Equity	0.60-0.1x	0.70-0.2x	0.92+0.2x	0.75-0.1x	0.80+0.1x	0.66+0.2x	0.420.0x	0.47+0.5x	0.00	N/A
Asset Turnover	0.350.0x	0.350.0x	0.310.0x	0.280.0x	0.29+0.1x	0.18-0.2x	0.340.0x	0.340.0x	0.32	N/A
FCF Margin	6.0%-2.9pp	8.9%+5.9pp	3.0%-3.4pp	6.4%-0.4pp	6.8%+12.2pp	-5.4%-8.1pp	2.7%-8.8pp	11.5%+8.9pp	2.6%+1.0pp	1.6%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	58.3%+0.9pp	57.3%-0.1pp	51.5%+0.6pp	53.4%+1.2pp	57.5%-0.7pp	57.3%+0.1pp	50.9%+0.7pp	52.2%-2.2pp
Net Margin	4.0%+3.1pp	4.2%-1.5pp	-24.1%-23.3pp	-3.0%-38.3pp	0.9%+5.1pp	5.6%+3.0pp	-0.8%+12.8pp	35.3%
Return on Equity	0.8%+0.7pp	0.9%-0.2pp	-4.2%-4.1pp	-0.5%-6.1pp	0.2%+1.0pp	1.1%+0.5pp	-0.1%+2.1pp	5.6%+23.4pp
Return on Assets	0.4%+0.3pp	0.4%-0.1pp	-2.1%-2.0pp	-0.3%-3.0pp	0.1%+0.4pp	0.5%+0.3pp	-0.1%+0.9pp	2.7%+10.4pp
Current Ratio	2.05-0.5x	2.16-0.6x	2.17-0.3x	2.40-0.1x	2.60-0.3x	2.71-0.6x	2.44-0.3x	2.55-0.3x
Debt-to-Equity	0.580.0x	0.60-0.1x	0.60-0.1x	0.59-0.1x	0.61-0.3x	0.68-0.3x	0.70-0.2x	0.66-0.3x
Asset Turnover	0.100.0x	0.100.0x	0.090.0x	0.080.0x	0.090.0x	0.090.0x	0.080.0x	0.080.0x
FCF Margin	17.8%+3.3pp	-2.8%+3.0pp	4.0%-8.7pp	11.2%-0.5pp	14.5%+0.5pp	-5.8%-3.9pp	12.8%+1.5pp	11.7%-3.8pp

Not reported in any period shown, so not listed: Operating Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Elanco Animal Health Incorporated ELAN	FY2025	$4.7B	-$232.0M	-4.9%	$11.2B	36/100
Alkermes Inc. plc ALKS	FY2025	$1.5B	$241.7M	16.4%	$7.2B	73/100
Lantheus Holdings, Inc LNTH	FY2025	$1.5B	$233.6M	15.2%	$6.5B	71/100
Indivior Pharmaceuticals, Inc. INDV	FY2025	$1.2B	$210.0M	17.0%	$4.2B	44/100
Viatris Inc. VTRS	FY2025	$14.3B	-$3.5B	-24.6%	$20.2B	28/100
Prestige Consumer Healthcare Inc. PBH	FY2026	$1.1B	$190.3M	17.5%	$2.2B	61/100

Where Elanco Animal Health Incorporated Ranks

Frequently Asked Questions

What is Elanco Animal Health Incorporated's annual revenue?

Elanco Animal Health Incorporated (ELAN) reported $4.7B in total revenue for fiscal year 2025. This represents a 6.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Elanco Animal Health Incorporated's revenue growing?

Elanco Animal Health Incorporated (ELAN) revenue grew by 6.2% year-over-year, from $4.4B to $4.7B in fiscal year 2025.

Is Elanco Animal Health Incorporated profitable?

No, Elanco Animal Health Incorporated (ELAN) reported a net income of -$232.0M in fiscal year 2025, with a net profit margin of -4.9%.

How much debt does Elanco Animal Health Incorporated have?

As of fiscal year 2025, Elanco Animal Health Incorporated (ELAN) had $545.0M in cash and equivalents against $3.9B in long-term debt.

What is Elanco Animal Health Incorporated's gross margin?

Elanco Animal Health Incorporated (ELAN) had a gross margin of 55.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Elanco Animal Health Incorporated's net profit margin?

Elanco Animal Health Incorporated (ELAN) had a net profit margin of -4.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Elanco Animal Health Incorporated's return on equity (ROE)?

Elanco Animal Health Incorporated (ELAN) has a return on equity of -3.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Elanco Animal Health Incorporated's free cash flow?

Elanco Animal Health Incorporated (ELAN) generated $284.0M in free cash flow during fiscal year 2025. This represents a -27.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Elanco Animal Health Incorporated's operating cash flow?

Elanco Animal Health Incorporated (ELAN) generated $560.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Elanco Animal Health Incorporated's total assets?

Elanco Animal Health Incorporated (ELAN) had $13.4B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Elanco Animal Health Incorporated's capital expenditures?

Elanco Animal Health Incorporated (ELAN) invested $276.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Elanco Animal Health Incorporated spend on research and development?

Elanco Animal Health Incorporated (ELAN) invested $368.0M in research and development during fiscal year 2025.

How many shares does Elanco Animal Health Incorporated have outstanding?

Elanco Animal Health Incorporated (ELAN) had 497M shares outstanding as of fiscal year 2025.

What is Elanco Animal Health Incorporated's current ratio?

Elanco Animal Health Incorporated (ELAN) had a current ratio of 2.17 as of fiscal year 2025, which is generally considered healthy.

What is Elanco Animal Health Incorporated's debt-to-equity ratio?

Elanco Animal Health Incorporated (ELAN) had a debt-to-equity ratio of 0.60 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Elanco Animal Health Incorporated's return on assets (ROA)?

Elanco Animal Health Incorporated (ELAN) had a return on assets of -1.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Elanco Animal Health Incorporated's P/E ratio?

Elanco Animal Health Incorporated (ELAN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $11.2B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Elanco Animal Health Incorporated's price-to-sales ratio?

Elanco Animal Health Incorporated (ELAN) trades at 2.2x sales, its market capitalization divided by revenue of $5.0B revenue, trailing 12 months to June 30, 2026. The market capitalization is $11.2B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Elanco Animal Health Incorporated's Piotroski F-Score?

Elanco Animal Health Incorporated (ELAN) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Elanco Animal Health Incorporated's earnings high quality?

Elanco Animal Health Incorporated (ELAN) reported a net loss of $232.0M while generating $560.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Elanco Animal Health Incorporated?

Elanco Animal Health Incorporated (ELAN) scores 36 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.